Prevalence of metabolic syndrome among antiretroviral-naive and antiretroviral-experienced HIV-1 infected Thai adults. 2014

Jureeporn Jantarapakde, and Nittaya Phanuphak, and Chintana Chaturawit, and Supabhorn Pengnonyang, and Pornpen Mathajittiphan, and Piyaporn Takamtha, and Narunat Dungjun, and Suteeraporn Pinyakorn, and Warabhorn Pima, and Wisit Prasithsirikul, and Praphan Phanuphak
1 Thai Red Cross AIDS Research Centre , Bangkok, Thailand .

Metabolic syndrome (MS), a group of interrelated risk factors for cardiovascular diseases (CVD) and type 2 diabetes, has been increasingly reported among HIV-infected patients. Data on the prevalence and risk factors for MS among HIV-1 infected Thai adults are limited. The study collected cross-sectional data from 580 HIV-1 infected adults-46.2% were men and 71% were antiretroviral therapy (ART)-experienced. The majority (78.8%) of them used non-nucleoside reverse transcriptase inhibitor-based regimens. Data on lipid profiles, fasting blood glucose, CD4 count, HIV RNA, antiretroviral therapy (ART), anthropometry, food intake, and exercise were recorded. MS was defined using American Heart Association/National Heart Lung and Blood Institute criteria. Overall prevalence of MS was 22.2%; 15.9% in ART-naïve group vs. 24.9% in ART-experienced group, p = 0.018. Significant risk factors for MS in multivariate analyses included age ≥35 years (odds ratio, OR, 4.2, 95%CI 1.6-11.0, p = 0.004), high cholesterol (OR 4.7, 95%CI 1.7-12.9, p = 0.002), and living outside Bangkok (OR 4.2, 95%CI 1.6-10.8, p = 0.003) in the ART-naïve group, and female gender (OR 1.7, 95%CI 1.0-2.8, p = 0.05), lipodystrophy (OR 1.8, 95%CI 1.0-3.0, p = 0.032), high cholesterol (OR 1.9, 95%CI 1.1-3.1, p = 0.015), and food insecurity (OR 1.8, 95%CI 1.0-3.3, p = 0.05) in the ART-experienced group. All variables, except for female gender in the ART-experienced group, remained significantly associated with MS in a model where lipodystrophy was excluded. We concluded that MS was common among HIV-1-infected Thai adults. As HIV-infected patients get older, early screening and intervention, such as ART modification to avoid lipodystrophy, may reduce MS and CVD-related morbidities and mortalities in long-term care.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor

Related Publications

Jureeporn Jantarapakde, and Nittaya Phanuphak, and Chintana Chaturawit, and Supabhorn Pengnonyang, and Pornpen Mathajittiphan, and Piyaporn Takamtha, and Narunat Dungjun, and Suteeraporn Pinyakorn, and Warabhorn Pima, and Wisit Prasithsirikul, and Praphan Phanuphak
October 2003, HIV medicine,
Jureeporn Jantarapakde, and Nittaya Phanuphak, and Chintana Chaturawit, and Supabhorn Pengnonyang, and Pornpen Mathajittiphan, and Piyaporn Takamtha, and Narunat Dungjun, and Suteeraporn Pinyakorn, and Warabhorn Pima, and Wisit Prasithsirikul, and Praphan Phanuphak
June 2018, AIDS patient care and STDs,
Jureeporn Jantarapakde, and Nittaya Phanuphak, and Chintana Chaturawit, and Supabhorn Pengnonyang, and Pornpen Mathajittiphan, and Piyaporn Takamtha, and Narunat Dungjun, and Suteeraporn Pinyakorn, and Warabhorn Pima, and Wisit Prasithsirikul, and Praphan Phanuphak
May 2014, Journal of medical microbiology,
Jureeporn Jantarapakde, and Nittaya Phanuphak, and Chintana Chaturawit, and Supabhorn Pengnonyang, and Pornpen Mathajittiphan, and Piyaporn Takamtha, and Narunat Dungjun, and Suteeraporn Pinyakorn, and Warabhorn Pima, and Wisit Prasithsirikul, and Praphan Phanuphak
December 2002, The Southeast Asian journal of tropical medicine and public health,
Jureeporn Jantarapakde, and Nittaya Phanuphak, and Chintana Chaturawit, and Supabhorn Pengnonyang, and Pornpen Mathajittiphan, and Piyaporn Takamtha, and Narunat Dungjun, and Suteeraporn Pinyakorn, and Warabhorn Pima, and Wisit Prasithsirikul, and Praphan Phanuphak
March 2001, Antiviral therapy,
Jureeporn Jantarapakde, and Nittaya Phanuphak, and Chintana Chaturawit, and Supabhorn Pengnonyang, and Pornpen Mathajittiphan, and Piyaporn Takamtha, and Narunat Dungjun, and Suteeraporn Pinyakorn, and Warabhorn Pima, and Wisit Prasithsirikul, and Praphan Phanuphak
December 2015, Medicine,
Jureeporn Jantarapakde, and Nittaya Phanuphak, and Chintana Chaturawit, and Supabhorn Pengnonyang, and Pornpen Mathajittiphan, and Piyaporn Takamtha, and Narunat Dungjun, and Suteeraporn Pinyakorn, and Warabhorn Pima, and Wisit Prasithsirikul, and Praphan Phanuphak
June 1998, AIDS (London, England),
Jureeporn Jantarapakde, and Nittaya Phanuphak, and Chintana Chaturawit, and Supabhorn Pengnonyang, and Pornpen Mathajittiphan, and Piyaporn Takamtha, and Narunat Dungjun, and Suteeraporn Pinyakorn, and Warabhorn Pima, and Wisit Prasithsirikul, and Praphan Phanuphak
December 2004, Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology,
Jureeporn Jantarapakde, and Nittaya Phanuphak, and Chintana Chaturawit, and Supabhorn Pengnonyang, and Pornpen Mathajittiphan, and Piyaporn Takamtha, and Narunat Dungjun, and Suteeraporn Pinyakorn, and Warabhorn Pima, and Wisit Prasithsirikul, and Praphan Phanuphak
February 2013, Journal of medical virology,
Jureeporn Jantarapakde, and Nittaya Phanuphak, and Chintana Chaturawit, and Supabhorn Pengnonyang, and Pornpen Mathajittiphan, and Piyaporn Takamtha, and Narunat Dungjun, and Suteeraporn Pinyakorn, and Warabhorn Pima, and Wisit Prasithsirikul, and Praphan Phanuphak
December 2012, BMC infectious diseases,
Copied contents to your clipboard!